OSE Immunotherapeutics SA

04/26/2021 | Press release | Distributed by Public on 04/26/2021 10:08

OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ[...]